MAZE: Maze Therapeutics Corp Analyst Consensus Forecast

Symbol and logo of brand Maze Tx (MAZE)

The experienced management of Maze Therapeutics Inc (MAZE) is effectively developing genetic platforms, leveraging a substantial liquidity reserve. Business resilience is secured through alliances with pharma behemoths, which guarantees capital inflows and mitigates risks. This price action chart reflects the current indicator 62.45. Looking ahead, the company plans to generate revenue by bringing unique therapies for severe hereditary pathologies to market.

Maze Tx (MAZE) - Analyst Consensus Forecast from 02/01/2025 to 11/12/2026
Manufactured products of mazetx.com

The intensive protein modeling work conducted by Maze Therapeutics Inc (MAZE) is reflected in the dynamics of the current consensus target price. This indicator represents the weighted average expected asset value provided by industry experts. The calculation is based on a comparison of the business's fundamental value with market quotes. The inflection points on the line capture the market's reaction to technological updates and reports, allowing investors to differentiate true growth drivers from short-term noise.

Competitors of Maze Therapeutics Inc

Consensus Target tempus.com TEM|Analyst Consensus Forecast QGEN (Qiagen)|Analyst Consensus Forecast Ionis Pharmaceuticals, Inc. IONS|RGEN: Consensus Target|Forecast Levels Chart RNA|CRSP: Analyst Consensus Forecast|Average Forecast Price genedx.com (WGS)|RARE (Ultragenyx) - Analyst Consensus Forecast|Broker Consensus Forecast BEAM (Beam Therapeutics Inc)|Price Target Chart Sarepta Therapeutics Inc (SRPT)|Twist Bioscience Corp - Broker Consensus Forecast|Analyst Consensus Forecast TXG (10x Genomics, Inc.)|Analyst Consensus Forecast intelliatx.com NTLA|STOK - Price Target Chart|BioLife Solutions Inc (BLFS) - Consensus Target|WVE: Analyst Consensus Forecast|Sionna Corp (SION) - Analyst Consensus Forecast|Consensus Target PRME|tayshagtx.com - Forecast Levels Chart|Analyst Consensus Forecast QURE|MGTX - Average Forecast Price|Regenxbio - Consensus Target|Fair Value Consensus SLDB|OCGN: Consensus Target|pacb.com - Analyst Forecast Prices|BNTC: Analyst Consensus Forecast|Design Therapeutics Inc - Fair Value Consensus|RCKT (Rocket Pharmaceuticals Inc) - Analyst Consensus Forecast|Average Forecast Price 4D Molecular Corp FDMT|Price Target Chart Lexeo Therapeutics (LXEO)|KRRO (korrobio.com) - Fair Value Consensus|Analyst Consensus Forecast EDIT (Editas Medicine)|Analyst Consensus Forecast Silence Therapeutics PLC SLN|PRQR - Price Target Chart|Forecast Levels Chart CDXS|SGMO: Analyst Consensus Forecast|Average Forecast Price Nautilus Bio (NAUT)|Consensus Target MGX|Analyst Consensus Forecast Precision BioSciences Inc.|Consensus Target GBIO (Generation Bio Co.)|Analyst Forecast Prices BOLD|Analyst Consensus Forecast XCUR (Exicure)|Analyst Median Target Imunon Inc (IMNN)|RXi Pharmaceuticals - Analyst Consensus Forecast|Mustang Bio, Inc. (MBIO) - Consensus Target|transcodetherapeutics.com (RNAZ) - Price Target Chart|BNGO - Analyst Median Target|Consensus Target APDN|BLUE: Fair Value Consensus|Analyst Consensus Forecast IPA|Analyst Median Target Omega Therapeutics Inc|Price Target Chart Singular Genomics Systems Inc OMIC|RGLS: Broker Consensus Forecast|Syros Pharmaceuticals - Analyst Consensus Forecast|telesisbio.com (TBIO) - Consensus Target|TRACON Pharmaceuticals, Inc. (TCON) - Price Target Chart|Consensus Target Unity Biotechnology Inc.